Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). The company also offers solutions for structural heart and endovascular procedures.
Mr. Christopher Simon is the President of Haemonetics Corp, joining the firm since 2016.
What is the price performance of HAE stock?
The current price of HAE is $66.4, it has increased 17.19% in the last trading day.
What are the primary business themes or industries for Haemonetics Corp?
Haemonetics Corp belongs to Health Care industry and the sector is Health Care
What is Haemonetics Corp market cap?
Haemonetics Corp's current market cap is $3.0B
Is Haemonetics Corp a buy, sell, or hold?
According to wall street analysts, 11 analysts have made analyst ratings for Haemonetics Corp, including 5 strong buy, 7 buy, 2 hold, 1 sell, and 5 strong sell